LPAA SEC filings, in plain English
Everything Launch One Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 40 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: A Limited Power of Attorney exhibit attached to an amended Schedule 13G, filed to delegate signature authority for Section 13(d) and 13(g) regulatory reporting. This filing does not alter the SPAC’s redemption deadline of 2027-01-15, the stated trust value per share of $10.86, any extension status, current deal progress, or sponsor conduct. Dated 8-13-2026 and signed by Shuji Matsuura and Adam Hopkins on behalf of Mizuho Financial Group, Inc., Mizuho Bank, Ltd., Mizuho Americas LLC, and Mizuho Securities USA LLC, the document merely grants Takahiro Katsura and appointed officers permission to execute Form 13G filings with the SEC. No adjustments to beneficial ownership percentages, acquisition targets, or liquidation mechanisms are disclosed in this exhibit. Why it matters: The document contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel movements relevant to a prospective business combination. It exclusively lists entity addresses at 1-5-5, Otemachi, Chiyoda-ku, Tokyo 100-8176, Japan and 1271 Avenue of the Americas, NY, NY 10020, USA and validates standard exchange act compliance protocols. Because it functions solely as an administrative authorization rather than an operational or transactional disclosure, it leaves LPAA’s SEARCHING status undisturbed, preserves the $10.86 per share trust reserve, and maintains the unextended timeline toward the 2027-01-15 deadline. Investors tracking capital return mechanics or deal execution should await subsequent proxy materials, tender offer notices, or business combination agreements for material developments.
What changed: Quarterly report (Form 10-Q) for a blank-check company still searching for a merger target. The trust was decimated. On July 10, 2026, 21,226,389 public shares (92% of the 23,000,000) were redeemed at ~$10.83 per share, removing ~$229.9 million from the trust. Post-redemption, only 1,773,611 public shares remain, with a trust valued at roughly $20 million. To pass the extension vote to January 15, 2027, the Sponsor converted 5,749,999 of its 5,750,000 founder shares into public shares and entered non-redemption agreements with investors, transferring 330,000 founder shares to those investors. The SPAC's prior deal (Minovia Therapeutics) was terminated on January 30, 2026. The Company drew the full $1,000,000 under a punitive working capital note (20% OID, 8% interest, 10% prepayment penalty) from the Sponsor, who in turn pledged 2,932,500 of its own shares to a third-party lender, Keystone Capital Partners. The working capital deficit expanded to $1.67 million, and the auditor's going-concern qualification is reiterated. Why it matters: This is a distressed SPAC, not a routine filing. The massive redemption essentially gutted the deal currency. Any future deal will be tiny (~$20M trust) and the SPAC's survival past January 15, 2027 depends on finding a target or another extension. The Sponsor's financial commitment is secured by a pledge of its own shares to a third party, creating a potential conflict if the SPAC liquidates: the third-party lender could seize a controlling stake. The onerous working capital note terms suggest the Sponsor is extracting maximum economic rent. The $10.86 trust value per share from the balance sheet is stale; the real post-redemption trust value is about $10.83.
What changed vs 2026-05-14trust $247.6M → $249.8M +1%deadline 2026-07-15 → 2027-01-15trust account, combination deadline, going-concern doubt +22 moved · 3 with no prior record of ours
- Trust account
- $247.6M$249.8M
- Combination deadline
- 2026-07-152027-01-15
- Going-concern doubt
- stated · unchanged
- Sponsor loans outstanding
- $308K · unchanged
- Redeemable shares
- 23.0M · unchanged
SpacBrain reads this as $2,193,256 was added to the trust between the two filings.
The clause …“68,844 Total current assets 460,082 181,176 Cash and marketable securities held in Trust Account 249,810,453 245,449,353 TOTAL ASSETS $ 250,270,535 $ 245,630,529 LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND”…
SpacBrain reads this as 184 days later than the previous record.
The clause …“of the Public Shares if the Company is unable to complete the initial Business Combination by January 15, 2027, or by such earlier liquidation date as the Company’s board of directors (the “Board”) may approve (the “Combination”…
The clause …“condition, the date of mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities”…
The clause …“Offering. From inception through the Initial Public Offering, the Company had borrowed $ 307,974 under the IPO Promissory Note. As of June 30, 2026 and December 31, 2025, the Company had borrowed $ 0 under the IPO Promissory Note. The”…
The clause …“value; 500,000,000 shares authorized; none issued or outstanding (excluding 23,000,000 shares subject to possible redemption) as of June 30, 2026 and December 31, 2025 — — Class B Ordinary Shares, $ 0.0001 par value; 50,000,000 shares”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: This document IS a Form 8-K current report that discloses the corporate actions and shareholder resolutions stemming from an extraordinary general meeting held on July 10, 2026. According to the Company’s disclosure, shareholders approved an Extension Amendment to the Articles of Association, moving the business combination deadline from July 15, 2026 to January 15, 2027. The Company executed Non-Redemption Agreements with multiple investors concerning an aggregate of 1,650,000 Class A ordinary shares. The Sponsor, Launch One Sponsor LLC, stated it would transfer 330,000 Class A ordinary shares to these investors after a business combination closes. The Board’s Audit Committee designated WithumSmith+Brown, PC as the independent registered public accounting firm for the year ending December 31, 2026. Concurrently, the Company reported that holders of 21,226,389 Public Shares validly exercised redemption rights at approximately $10.83 per share, generating an aggregate redemption amount of approximately $229.9 million. Following these transactions, the Company stated there are 1,773,611 Public Shares currently issued and outstanding. Why it matters: The contractual extension grants management and the Board an additional six months to identify and close a target acquisition before trigger events force liquidation. The Sponsor’s commitment to assign 330,000 founder shares to participants of the 1,650,000-share non-redemption pool signals a deliberate mechanism to offset dilution and incentivize capital retention, directly altering post-combination equity distribution mechanics. The exercise of 21,226,389 redemptions at $10.83 substantially drains the available trust capital, leaving only 1,773,611 public shares to back future valuation benchmarks. Management explicitly confirmed that the Trust Account will not be tapped to cover any potential Inflation Reduction Act of 2022 excise taxes arising from the redemptions. Beyond these timeline, liquidity, and capital structure adjustments, the filing contains no verifiable claims regarding customers, revenue, market size, operational strategy, technology, commercial partnerships, ongoing litigation, or executive personnel changes.
What changed: Form 8-K Current Report (Items 3.02 and 8.01) documenting an unregistered equity conversion and proposing non-redemption agreements ahead of a shareholder vote. Per the filing dated July 6, 2026, the Company converted 5,749,999 Class B ordinary shares into Class A ordinary shares, leaving 28,749,999 Class A and 1 Class B share outstanding. Regarding redemption and extension mechanics, the proxy statement filed June 10, 2026 calls an extraordinary general meeting to vote on an amendment extending the business combination deadline from July 15, 2026 to January 15, 2027. To preserve trust capital, the Sponsor plans to execute Non-Redemption Agreements with selected investors. Under these agreements, investors waive redemption rights (or rescind pending requests) and vote in favor of the extension. In return, the Sponsor anticipates transferring a negotiated volume of its Class A shares to those investors promptly after any future business combination closes. The filing notes these agreements automatically terminate if the extension fails, obligations are satisfied, the Company liquidates, parties mutually agree, or an investor redeems or votes against the proposal. Management states the arrangements are expected to increase approval odds and maximize funds retained in the trust account. Why it matters: Beyond the extension mechanics, the filing confirms the warrant structure at $11.50 per share exercisable for one Class A ordinary share, restates the definitive proxy timeline (mailed to May 15, 2026 record-date holders around June 12, 2026, with supplemental materials added June 25, 2026), and carries Chief Executive Officer Chris Ehrlich’s signature authorizing the report on July 6, 2026. From an investment standpoint, this submission materially shifts the liquidity horizon six months forward, reduces immediate per-share trust dilution risk through sponsored non-redemption commitments, and explicitly acknowledges the original acquisition timeline was insufficient. Shareholders now hold a binding contractual choice between early cash-out under the original deadline or accepting extended search duration plus sponsor equity consideration in exchange for retaining their principal.
What changed: A Current Report on Form 8-K filed by Launch One Acquisition Corp. announcing the postponement of a shareholder vote to approve an amendment extending the deadline to consummate an initial business combination. Launch One Acquisition Corp. has rescheduled its extraordinary general meeting to consider an amendment to extend the business combination deadline from July 15, 2026 to January 15, 2027. The meeting is now set for Friday, July 10, 2026, at 10:00 a.m., Eastern Time, initially scheduled for Tuesday, July 7, 2026. Accordingly, the deadline for shareholders to exercise redemption rights related to the Extension Amendment Proposal is pushed back to Wednesday, July 8, 2026, at 5:00 p.m., Eastern Time. The meeting location remains the offices of Ellenoff Grossman & Schole LLP, located at 1345 Avenue of the Americas, 11 th Floor, New York, New York 10105. Why it matters: As disclosed in the filing, the company mailed the Proxy Statement to shareholders as of the May 15, 2026 record date beginning on or about June 12, 2026. Chief Executive Officer Chris Ehrlich authorized the report. This scheduling shift adjusts the critical redemption window for the $10.86 trust/shares ahead of the January 15, 2027 liquidation horizon, with no alterations to the underlying six-month extension mechanics or the $11.50 whole warrant exercise price detailed in the document. Investors tracking the extension vote must align liquidity actions with the new July 8, 2026 deadline.
What changed: A Form 8-K Current Report and accompanying DEFA14A Definitive Additional Materials filed by Launch One Acquisition Corp. to formally announce the postponement of a shareholder meeting and to update the calendar for exercising redemption rights in connection with a proposed amendment to extend the company's business combination timeline. Launch One Acquisition Corp. has rescheduled its extraordinary general meeting from Tuesday, July 7, 2026, to Friday, July 10, 2026. In direct response, the Company has pushed the redemption exercise deadline to Wednesday, July 8, 2026, at 5:00 p.m., Eastern Time. The substantive proposal remains identical: shareholders are being asked to approve amendments to the memorandum and articles of association that would extend the deadline to consummate an initial business combination from July 15, 2026, to January 15, 2027. The meeting location remains the offices of Ellenoff Grossman & Schole LLP in New York, and the record date stays fixed at May 15, 2026. Why it matters: This filing directly reindexes the redemption and proxy voting schedule ahead of the original July 15, 2026, liquidation trigger. Shareholders now have until July 8, 2026, to submit redemption requests before the rescheduled July 10, 2026, vote on the six-month extension proceeds. The postponement does not introduce new claims regarding customers, revenue, market size, technology, partnerships, litigation, or sponsor conduct. As executed by Chief Executive Officer Chris Ehrlich, the communication contains no offer or solicitation beyond the proxy materials already distributed beginning on or about June 12, 2026. Investors must monitor the shifted July 8, 2026, redemption cutoff closely, as failure to act by that precise time may force cash retention or trigger conversion mechanics if the extension vote ultimately fails.
What changed: Definitive Proxy Statement convened by Launch One Acquisition Corp. to solicit shareholder votes at an Extraordinary General Meeting in lieu of an Annual General Meeting. The filing proposes amending the Company’s Articles to extend the deadline to consummate an initial business combination from July 15, 2026, to January 15, 2027. It activates a shareholder redemption election exercisable prior to 5:00 p.m. Eastern Time on July 2, 2026, priced at approximately $10.83 per share based on a reported Trust Account balance of approximately $249,132,955 as of June 2, 2026. The document confirms a Working Capital Promissory Note executed on March 20, 2026, authorizing the Sponsor to lend up to $1,000,000 across three tranches, secured by a pledge of 2,932,500 founder shares to Keystone Capital Partners, LLC. The Sponsor states it intends to vote all 5,750,000 founder shares in favor of the extension and related proposals. Why it matters: According to the proxy statement, the Board concludes that there may not be sufficient time before July 15, 2026, to conduct a separate shareholder vote for a Potential Business Combination and consummate a closing without this extension. Shareholders face a direct liquidity decision: tender shares for redemption at the calculated pro rata trust value before the July 2, 2026 deadline, or retain exposure to a search period where the company discloses having no definitive agreement with a target entity. The filing warns that large-scale redemptions could deplete trust cash below thresholds required for business combination closing conditions or trigger Nasdaq delisting proceedings, as the exchange generally requires a minimum of 400 public holders. Management also discloses that 6,000,000 private placement warrants were previously issued to Sponsor and Cantor Fitzgerald & Co. at $1.00 each, totaling $6,000,000 in gross IPO-side proceeds, with an exercise price of $11.50 per share that remains unexercised until after a business combination. The working capital facility carries an 8% annual interest rate, a 20% original issue discount, and defaults interest at an additional 18%, with repayment dependent on successful deal execution. Furthermore, the filing notes audit fees of $116,895 for the year ended December 31, 2025 and $128,440 for the inception period through December 31, 2024, paid to WithumSmith+Brown, PC, whose appointment the Board recommends ratifying. The Board attributes all extension recommendations to fiduciary assessments that continuing the search period serves shareholder interests by preserving optionality for a Potential Business Combination valuation event.
What changed: Revised Preliminary Proxy Statement (PRER14A) for Launch One Acquisition Corp. convening an Extraordinary General Meeting in lieu of an Annual General Meeting to solicit shareholder votes on a business combination deadline extension, auditor ratification, and adjournment authority. The Board proposes amending the Amended and Restated Memorandum and Articles of Association to extend the deadline to consummate an initial business combination from July 15, 2026, to January 15, 2027. According to the Board, public shareholders may exercise an 'Election' to redeem Class A ordinary shares immediately upon the extension’s effectiveness at a per-share price calculated using the exact aggregate Trust Account deposits and interest, divided by then-issued public shares. The Board states that if the Extension passes but no deal closes by the Extended Date, operations will cease, public shares will be redeemed from remaining Trust funds, and all warrants will expire worthless. Sponsor Launch One Sponsor LLC controls 5,750,000 founder shares (20.0% of outstanding shares) and discloses its intent to vote 'FOR' all proposals. The Board details a Working Capital Promissory Note enabling Sponsor to lend up to $1,000,000 in three tranches consisting of an initial $500,000 and two subsequent $250,000 installments, carrying a 20% original issue discount, 8% annual interest, a 26% default interest rate, and a 10% prepayment penalty (subject to consent). To secure related lender obligations, Sponsor pledges 2,932,500 Class B ordinary shares (approximately 51% of its founder stake) to Keystone Capital Partners, LLC as agent, with the filing noting the loans are non-recourse to Sponsor and lender recourse is limited to the pledged collateral. Okapi Partners LLC receives a fixed $15,000 fee plus expense reimbursement for proxy solicitation. The filing leaves specific Trust Account balances and precise meeting/redemption deadlines as placeholders ('$ ', '[ ● ]') due to its preliminary status. On-screen data confirms the SPAC completed its IPO on July 15, 2024, generating $230,000,000 in gross proceeds and selling 6,000,000 private placement warrants at $1.00 each to Sponsor and Cantor Fitzgerald & Co. Why it matters: This amendment fundamentally resets the SPAC’s survival timeline and activates an immediate liquidity option for investors who reject prolonged capital deployment risk. According to the Board, each executed Election drains proportional Trust Account capital, which management acknowledges could leave insufficient liquidity to satisfy potential target closing conditions, thereby elevating reliance on the $1,000,000 sponsor working capital facility or alternative financing. The sponsor’s pledge of 2,932,500 founder shares to secure the credit agreement introduces direct collateral risk to insider equity if the Company liquidates without a merger. The Board also warns that mass redemptions triggered by this amendment could reduce public holder counts below Nasdaq’s generally required 400-public-holder threshold, potentially triggering delisting procedures that would restrict secondary market liquidity and impose penny stock trading regulations. The Board unanimously recommends approval, and with the Sponsor’s committed 20.0% voting block controlling the Founder Shares, the critical two-thirds supermajority threshold for Cayman Islands special resolutions becomes structurally manageable, though final outcomes remain strictly contingent on independent public shareholder Elections. Auditor fees of approximately $116,895 for fiscal year 2025 and $128,440 for the period from inception through December 31, 2024 were paid to WithumSmith+Brown, PC, whom the Audit Committee nominated for ratification. Director and officer groups (Ryan Gilbert, Chris Ehrlich, Jurgen van de Vyver, Brian Atwood, Rodney A. Ferguson, and Risa Stack) disclaim individual beneficial ownership of the 5,750,000 founder shares held by the Sponsor. All projections regarding Potential Business Combinations, regulatory CFIUS review risks, PFIC tax implications, Nasdaq compliance thresholds, and sponsor lending economics are attributed exclusively to Launch One Acquisition Corp.’s Board of Directors, executive management, the Audit Committee, or the Sponsor as formally disclosed in this filing.
What changed: An SEC Form 8-K (Item 5.02) reporting the resignation of Director and Audit Committee Chair Dr. Risa Stack and the appointment of Director Daniel Clifford Rogers as her replacement and new Audit Committee Chair. Effective June 2, 2026, Dr. Risa Stack stepped down from the board and all committee roles. The board immediately appointed Daniel Clifford Rogers, age 56, to fill the vacancy and named him chair of the audit committee. As part of his appointment, Mr. Rogers executed joinders to the company's existing Letter Agreement (dated July 11, 2024) and Registration Rights Agreement (dated July 11, 2024). Per the Letter Agreement, he committed to waiving certain redemption rights and voting any ordinary shares he holds in favor of an initial business combination. The filing explicitly states that Dr. Stack's departure was not caused by any disagreement with the company regarding its operations, policies, or practices. Mr. Rogers also entered into a standard director indemnity agreement. Why it matters: This filing expands the pool of insiders bound by the July 11, 2024 Letter Agreement, adding another guaranteed vote in favor of a future business combination and locking in additional shares against early redemption at closing. The appointment introduces a director with specialized experience in the fintech and SaaS sectors (former CFO of Newcourt Acquisition Corp., Papaya Growth, and Helpshift; former CEO/Founder of FintechForce), which may align with the SPAC's target industry search. There are no updates to the capital structure, the per-share trust value remains cited at $10.86, and the redemption/extenuation deadline remains firmly set for January 15, 2027. The clean break noted with the departing director suggests no current friction between management and the board, supporting continued operational progress toward a deal before the deadline.
What changed: A Form 3 initial statement of beneficial ownership filing for Launch One Acquisition Corp. Per the SEC submission, director Daniel C. Rogers reported no non-derivative transactions or holdings. The document contains no references to redemption deadlines, trust value mechanics, extension provisions, target acquisition progress, or sponsor behavior. Why it matters: As a routine administrative disclosure, the filing does not adjust the company’s redemption calendar, modify trust account protections, or signal movement toward a business combination. Because the filing text explicitly states no insider positions changed, there is no immediate indication of altered sponsorship alignment or director confidence relative to public shareholders. Investors seeking developments on financing commitments, target due diligence timelines, or potential extension votes should await subsequent proxy statements, Form 8-K operational updates, or recorded earnings calls.
What changed: Preliminary Proxy Statement (Form PRE 14A) convening an Extraordinary General Meeting to solicit shareholder votes on a corporate charter extension and meeting adjournment proposal. The filing advances a proposal to amend the Articles to push the business combination deadline from July 15, 2026 to January 15, 2027, permitting monthly extensions up to [ ● ] times until [ ● ]. The board states it lacks a definitive agreement for a Potential Business Combination and believes insufficient time remains before the original July 15, 2026 cutoff to secure shareholder approval for a transaction. Accordingly, the filing establishes a concurrent Election allowing public shareholders to redeem shares for a per-share cash price calculated as the aggregate Trust Account balance divided by public shares then in issue, with physical or DWAC tenders required prior to 5:00 p.m. Eastern Time on [ ● ], 2026. On the May 15, 2026 record date, the company had 28,750,000 ordinary shares outstanding, comprising 23,000,000 public shares and 5,750,000 founder shares. The board states approval demands a special resolution of at least two-thirds of voting shares present. The Sponsor, Launch One Sponsor LLC, holds all 5,750,000 founder shares (20.0% of total) and intends to vote FOR the proposals. The Sponsor has pledged 2,932,500 founder shares to Keystone Capital Partners, LLC as collateral under a Credit Agreement financing up to $1,000,000 in loans to the Company ($500,000 initial tranche, two subsequent $250,000 tranches). The Company states it hired Okapi Partners LLC for proxy solicitation at a flat fee of $15,000 plus reimbursable expenses. The filing warns that substantial Election redemptions could drain the Trust Account, potentially causing future deals to fail unless acquirers waive closing conditions. Should the extension fail, dissolution proceedings would begin within 10 business days, with up to $100,000 of interest deductible for wind-down costs. The board notes that six million private placement warrants, originally sold at $1.00 apiece to the Sponsor and Cantor Fitzgerald & Co. for $6,000,000 gross proceeds, will expire worthless upon liquidation, as they carry a $11.50 exercise price. The July 15, 2024 IPO placed $230,000,000 in gross proceeds into the Trust Account, currently invested in Treasury bills maturing in 185 days or less. Why it matters: This PRE 14A forces an immediate liquidity and timeline bifurcation for public shareholders without the anchor of an announced merger. Because the board explicitly confirms there is no target, the extension operates strictly as administrative runway rather than deal-execution progress. Investors face a dual redemption architecture—immediate Election and future business combination votes—which the board cautions could create a liquidity vacuum that starves prospective acquirers of required cash. The Sponsor’s economic exposure is fully transparent: founder shares and private warrants carry zero liquidation value if the company winds up by July 15, 2026, while the Sponsor has leveraged over half its founder equity to secure external debt expressly to fund extension-period overhead. The $15,000 proxy solicitation expenditure and permitted insider open-market share purchases signal active capital allocation to secure the required two-thirds Cayman Islands threshold. Calendar trackers will adjust the absolute liquidation floor to January 15, 2027, subject to monthly renewals, though the board flags Nasdaq delisting risk if post-redemption public holder concentrations drop below 400. Additionally, the filing supplies detailed PFIC tax guidance, advising U.S. Holders that IRS treatment of redemption proceeds as distributions may strip preferential capital gains rates due to passive asset classification, triggering default PFIC taxation with ordinary income allocation and interest penalties on deferred gains.
What changed: 10-Q quarterly report for Launch One Acquisition Corp. (LPAA) for the period ended March 31, 2026. The Minovia Business Combination Agreement was terminated on January 30, 2026; the company is now seeking alternative targets. A Working Capital Note was executed on March 20, 2026, allowing up to $1,000,000 in loans from the Sponsor (initial $500,000 drawn), with the Sponsor pledging 2,932,500 Class B Ordinary Shares (≈51% of Founder Shares) as collateral under a Credit and Pledge Agreement. Trust account value per share increased from $10.67 at Dec. 31, 2025 to $10.77 at Mar. 31, 2026. Why it matters: The termination of the Minovia deal leaves LPAA without a business combination target less than four months before the July 15, 2026 deadline, raising the risk of liquidation. The new secured working capital loan and pledge of founder shares indicate the Sponsor is financially supporting the search but also creating potential control risks if defaults occur. The trust value per share of $10.77 still provides a modest floor for public shareholders.
What changed vs 2025-11-13trust $243.1M → $247.6M +2%trust account, combination deadline, going-concern doubt +21 moved · 4 with no prior record of ours
- Trust account
- $243.1M$247.6M
- Combination deadline
- 2026-07-15 · unchanged
- Going-concern doubt
- stated · unchanged
- Sponsor loans outstanding
- $308K · unchanged
- Redeemable shares
- 23.0M · unchanged
SpacBrain reads this as $4,534,453 was added to the trust between the two filings.
The clause …“68,844 Total current assets 451,902 181,176 Cash and marketable securities held in Trust Account 247,617,197 245,449,353 TOTAL ASSETS $ 248,069,099 $ 245,630,529 LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND”…
The clause …“of the Public Shares if the Company is unable to complete the initial Business Combination by July 15, 2026, or by such earlier liquidation date as the Company’s board of directors (the “Board”) may approve (the “Combination”…
The clause …“condition, the date of mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities”…
The clause “Offering. Since inception through the Initial Public Offering, the Company had borrowed $ 307,974 under the IPO Promissory Note. The Company repaid $ 335,314 on July 15, 2024. Due from Sponsor The Company paid the Sponsor an amount $”…
The clause …“value; 500,000,000 shares authorized; none issued or outstanding (excluding 23,000,000 shares subject to possible redemption) as of March 31, 2026 and December 31, 2025 — — Class B Ordinary Shares, $ 0.0001 par value; 50,000,000”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed by Launch One Acquisition Corp. (LPAA), a blank check company searching for a business combination. The trust value increased to $245,449,353 ($10.67 per share) from $235,529,521 ($10.24 per share) as of December 31, 2024, due to interest income of $9,919,832. The company's previously announced business combination with Minovia Therapeutics was terminated on January 30, 2026. On March 20, 2026, the sponsor entered into a Working Capital Promissory Note for up to $1,000,000 to fund operations, pledging 2,932,500 Class B shares (51% of founder shares) as collateral. Cash outside the trust fell to $30,146, and the company now has a working capital deficit of $609,961. Management has identified substantial doubt about the company's ability to continue as a going concern. The deadline to complete a business combination is July 15, 2026. Why it matters: The trust value per share is $10.67, below the $10.86 assumed by the user, and the liquidation deadline is July 15, 2026, not January 15, 2027. The termination of the Minovia deal resets the search to zero with less than four months left before forced liquidation. The sponsor's pledge of majority founder shares to secure working capital indicates financial stress and potential control implications if an extension or deal is not achieved. The going concern warning and low cash reserves heighten the risk of no deal and a forced redemption at approximately $10.67 per share, less any expenses.
What changed vs 2025-03-26trust $235.5M → $245.4M +4%deadline 2027-07-11 → 2026-07-15going concern APPEAREDtrust account, combination deadline, going-concern doubt +23 moved · 2 with no prior record of ours
- Trust account
- $235.5M$245.4M
- Combination deadline
- 2027-07-112026-07-15
- Going-concern doubt
- not statedstated
- Sponsor loans outstanding
- not previously extracted$308K
- Redeemable shares
- 23.0M · unchanged
SpacBrain reads this as $9,919,832 was added to the trust between the two filings.
The clause …“As of December 31, 2025 and December 31, 2024, we had marketable securities held in the Trust Account of $245,449,353 and $235,529,521, respectively (including $9,919,832 and $5,404,164 of interest income, respectively). We may”…
SpacBrain reads this as 361 days earlier than the previous record.
The clause …“of the Public Shares if the Company is unable to complete the initial Business Combination by July 15, 2026, or by such earlier liquidation date as the Company’s board of directors (the “Board”) may approve (the “Combination”…
SpacBrain reads this as the substantial-doubt sentence is in this filing and not in the previous one.
The clause …“the time and costs of completing an initial Business Combination; ● there is substantial doubt about our ability to continue as a “going concern”; ● if our initial Business Combination involves a company organized under the laws of a”…
The clause …“of December 31, 2024 or the completion of our Initial Public Offering. We borrowed $307,974 under the IPO Promissory Note and $335,314 was paid to the Sponsor upon the consummation of our Initial Public Offering on July 15, 2024,”…
The clause …“value; 500,000,000 shares authorized; none issued or outstanding (excluding 23,000,000 shares subject to possible redemption) as of December 31, 2025 and 2024 — — Class B Ordinary Shares, $ 0.0001 par value; 50,000,000 shares”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: An SEC Form 425/8-K Current Report filed by Launch One Acquisition Corp. disclosing the execution of a Working Capital Promissory Note, a Credit Agreement with Keystone Capital Partners, LLC, and a Pledge Agreement securing the underlying lending facility. Per the Registrant’s filings, the Company executed a Working Capital Note with its Sponsor, Launch One Sponsor, LLC, receiving an initial $500,000 tranche on March 20, 2026. The note structures two additional $250,000 tranches that the Sponsor may elect to fund specifically when the Company (A) enters into a letter of intent, memorandum of understanding, or other agreement regarding an initial business combination, or (B) calls a shareholder meeting to extend its deadline to consummate an initial business combination. To finance these advances, Keystone Capital Partners, LLC agreed via a Credit Agreement to lend the Sponsor up to $1,000,000 on a non-recourse basis, secured solely by a Pledge Agreement covering 2,932,500 Class B ordinary shares, representing approximately 51% of the Sponsor’s founder shares. The Sponsor and Cantor Fitzgerald & Co. entered a waiver letter to permit this pledge despite existing Insider Letter transfer restrictions. Crucially, Section 11 of the note includes an irrevocable trust account waiver confirming the Payee holds no claim to the Trust Account or public distributions, preserving the public shareholder trust balance from lender encumbrance. Why it matters: The Registrant’s board of directors and management stated the financing addresses limited year-end cash balances to cover operational expenses and prior business combination efforts. However, the note records a 20% original issue discount, setting the maximum face principal at $1,250,000 against $1,000,000 in actual draws, accruing 8% annual interest with an 18% default adder totaling 26%, and imposing a 10% prepayment penalty. On the issuance date, the Company agreed to withhold up to $25,000 from the initial tranche to reimburse the Sponsor’s funding costs, with additional out-of-pocket reimbursements for refinancing or enforcement capped at $20,000 per occurrence. Because lender recourse is strictly limited to the pledged founder shares and the debt matures upon business combination consummation or liquidation, the Sponsor bears the direct economic risk of failure without jeopardizing public shareholder trust assets. For investors tracking the redemption calendar and extension timeline, the explicit conditioning of the two $250,000 drawdowns on a shareholder extension vote confirms that operational runway remains tied to continued approval, while the steep implicit borrowing costs and expense offsets will further reduce net capital available for transaction pursuit.
What changed: A Form 8-K current report detailing the execution of a Working Capital Promissory Note between Launch One Acquisition Corp. and its sponsor, alongside related credit and pledge agreements with a third-party lender. According to the March 26, 2026 filing, the company entered into a promissory note on March 20, 2026, permitting borrowings up to $1,000,000. The Working Capital Note specifies an initial loan of $500,000 recorded with a $625,000 principal to account for a 20% original issue discount. Two subsequent tranches of $250,000 each may be drawn at the sponsor's sole discretion if the company executes a letter of intent for a business combination or calls a shareholder meeting to extend its deadline; each carries a $312,500 recorded principal. The note stipulates 8% annual interest that escalates to 26% upon default, with maturity triggered by the earlier of business combination completion or liquidation. Concurrently, the Sponsor executed a Credit Agreement with Keystone Capital Partners, LLC to finance these loans, pledging 2,932,500 Class B ordinary shares (representing approximately 51% of founder shares) as non-recourse collateral. The Pledge Agreement grants lenders foreclosure rights solely over the pledged shares. The filing documents a waiver of Insider Letter transfer restrictions to allow the pledge, and formally incorporates a trust waiver whereby the sponsor irreversibly relinquishes any claims against the trust account or public distributions. Why it matters: This transaction directly modifies extension mechanics and sponsor risk profiles. Management cited the company's 'limited cash balance at year end' as the rationale for securing additional working capital, effectively using sponsored debt to fund ongoing operations and avoid forced liquidation votes, thereby keeping the redemption calendar intact. However, by borrowing $1,000,000 from external lenders and encumbering over half of its founder equity, the sponsor has tied its own financial exposure to achieving a deal or successfully extending the deadline. The Credit Agreement creates hard deadlines, defining events of default if the company fails to file an extension proxy or execute a definitive merger agreement by specified dates, which intensifies schedule pressure on management. Cost structures embedded in the note include a $25,000 expense withholding on the initial draw and caps of $20,000 per occurrence for refinancing or enforcement costs, reducing net capital available for targets or general overhead. Standard security parameters noted in the cover page confirm warrants maintain a $11.50 exercise price. Crucially, the trust waiver ensures that neither corporate liabilities nor the sponsor's third-party creditors can access IPO trust proceeds, insulating public redemption values from this financing maneuver while highlighting increased reliance on sponsor-funded bridge capital ahead of a transaction.
What changed: A routine compliance exhibit containing a joint filing agreement accompanying an amended Schedule 13G beneficial ownership report. The provided text discloses no updates to share quantities, ownership percentages, or acquisition benchmarks. It notes no alterations to the 2027-01-15 redemption deadline, the $10.86 reported trust value per share, extension mechanisms, or sponsor management conduct. Signatories Ulla Vestergaard, identified as Director, and Hillel Meltz, identified as President, merely confirm mutual administrative responsibility for the joint submission dated February 12, 2026. Why it matters: Because the excerpt isolates only the procedural acknowledgment, it conveys zero actionable intelligence regarding redemption pressure, liquidity thresholds, or business combination execution. Investors cannot assess threshold crossings, block trade implications, or governance shifts without the principal Schedule 13G/A data schedules. Until those exhibits are examined, this document remains mechanically inert for portfolio monitoring.
What changed: This document is Exhibit 99.1, a Joint Filing Agreement appended to a Schedule 13G/A (SEC filing number [0000912282-26-000321]). In its own terms, it is a procedural declaration confirming that MMCAP International Inc. SPC and MM Asset Management Inc. have mutually agreed to submit the referenced beneficial ownership statement jointly, and that all subsequent amendments will also be filed on their combined behalf without executing further joint filing agreements. Each undersigned party accepts personal responsibility for the timeliness, completeness, and accuracy of its own disclosed information, while expressly disclaiming liability for the other party's data unless the signing party knows or has reason to believe that specific information is inaccurate. The agreement bears a February 12, 2026 date and is signed by Ulla Vestergaard, identified as Director, and Hillel Meltz, identified as President. The provided text discloses no modifications to aggregate share counts, beneficial ownership percentages, acquisition dates, or cost basis. Because this excerpt contains exclusively the joint filing covenant, it reports zero adjustments to blockholder voting power, tender offer coordination, or governance rights that would interface with Launch One Acquisition Corp.’s (LPAA) redemption mechanics, trust account oversight, extension approvals, or sponsor conduct rules. The filing solely re-establishes the joint reporting framework for the named entities; it does not alter the SPAC’s searching period expiration (January 15, 2027) or influence how the $10.86 per share trust balance is administered. Why it matters: For investors monitoring LPAA’s capital structure and deal timeline, this joint arrangement instructs market participants to treat MMCAP International Inc. SPC and MM Asset Management Inc. as a single consolidated shareholder group for all future Section 13(d) disclosures. It carries no immediate triggers for redemption windows, trust value dilution, target negotiation milestones, or sponsor compensation adjustments. The document contains no assertions regarding LPAA’s customer base, historical or projected revenue, addressable market sizing, corporate strategy, proprietary technology, commercial partnerships, pending litigation, or executive transitions beyond the two signatories named. Its sole utility is regulatory transparency, ensuring that any accumulated or divested position movement by these holders is reported consistently ahead of the January 15, 2027 business combination deadline.
What changed: Schedule 13G/A beneficial ownership report. Barclays PLC submits this filing to update its standard beneficial ownership records and identify itself as the reporting holder. Barclays PLC discloses nothing regarding LPAA’s redemption deadline, trust account value, extension elections, target acquisition progress, or sponsor conduct. Barclays PLC makes no statements about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. Why it matters: As a routine SEC compliance submission, this Schedule 13G/A confirms only a continuing reporting obligation for Barclays PLC. Because Barclays PLC provides no voting commitments, business combination announcements, or financial assertions, the filing does not advance LPAA’s search timeline, alter the per-share trust balance, trigger or waive any redemption rights, or inform investors about extension decisions or sponsor behavior. Tracking these specific mechanics reveals no operational or structural developments from this submission.
What changed: A Limited Power of Attorney (Exhibits A and B) submitted as an administrative appendix to a Schedule 13G, wherein Mizuho Financial Group, Inc., Mizuho Bank, Ltd., Mizuho Americas LLC, and Mizuho Securities USA LLC authorize designated corporate officers to execute and submit Section 13(d) and Section 13(g) ownership reports to the SEC. The filing contains no modifications to LPAA’s redemption mechanics, trust account valuation, liquidation or extension deadline, business combination status, or sponsor conduct. Executive signatories Hidekatsu Take and Adam Hopkins instead attest that they have delegated signature authority to Takahiro Katsura exclusively for preparing and filing 13G forms and associated amendments on behalf of the named Mizuho entities, leaving the SPAC’s structural and operational timeline unaltered. Why it matters: Investors monitoring deadline proximity, trust preservation, extension voting, target acquisition progress, or sponsor behavior will find no impact on any of those variables. Regarding other substantive disclosures, the document asserts nothing regarding customer concentration, revenue metrics, market sizing, strategic positioning, technology development, partnership arrangements, litigation exposure, or leadership changes beyond the titles of the signatories. The text functions strictly as a regulatory housekeeping instrument confirming Mizuho’s continued capacity to satisfy institutional reporting obligations without introducing new commercial or governance developments.
What changed: A Schedule 13G beneficial ownership report. This document is a Schedule 13G beneficial ownership report identifying W. R. Berkley Corporation and Berkley Insurance Company as listed holders. Regarding SPAC mechanics: the filing contains zero updates to the redemption deadline (2027-01-15), trust value ($10.86 per share), extension provisions, deal progress, or sponsor conduct. It discloses no acquisition target, no amendment history, and no shareholder vote results. Regarding other substance: the document makes no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. It reports only two holding entity names without ownership percentages, aggregate share counts, purpose statements, or footnote disclosures typically found in the body of a 13G. Why it matters: Investors tracking the 2027-01-15 redemption window and $10.86 trust floor should note that no mechanical or strategic variables shifted. The complete absence of percentage thresholds, acquisition notices, or extension requests confirms the search phase continues uninterrupted. However, the listed insurance-group beneficiaries represent concentrated institutional buckets whose voting leverage could become decisive upon a future business combination notice, making this a baseline register of passive position-holding rather than a near-term redemption or liquidity trigger.
What changed: A Form 8-K current report filed pursuant to Rule 425 under the Securities Act, functioning as a Rule 425 written communication that reports Item 1.02 (Termination of a Material Definitive Agreement) and attaches Exhibit 10.1, a Termination and Release Agreement dated January 30, 2026. Per the filing signed by Chief Executive Officer Chris Ehrlich, the Company and its sponsor mutually agreed to terminate the Business Combination Agreement with Minovia Therapeutics Ltd., Natalie Yivgi-Ohana in her capacity as Seller Representative, Mito US One Ltd., and Mito Sub Israel Ltd., effective January 30, 2026. Pursuant to the executed Termination and Release Agreement, each party released the others from all liabilities and damages relating to the transaction documents, while expressly noting that Section 9.1 of the original agreement (Waiver of Claims Against Trust) continues to apply. All ancillary agreements, including voting agreements, lock-up agreements, and the Sponsor Letter Agreement, were automatically terminated. Concurrently, the registrant and sponsor stated they currently intend to seek alternative ways to consummate an initial business combination. No amendment or extension mechanics were triggered, and the registered Class A ordinary shares retain a par value of $0.0001 per share while warrants maintain an exercise price of $11.50 per share. Why it matters: The execution of this release legally extinguishes the proposed transaction, removing merger-related equity dilution, management compensation triggers, and target-specific valuation assumptions from the capital structure. By preserving the trust waiver provision, the filing ensures that shareholder redemption rights and principal protection mechanisms remain fully enforceable if the SPAC liquidates during its remaining search period. Investors tracking the calendar should prepare for the sponsor’s next procedural step—either a targeted acquisition announcement, a proxy solicitation for a trust extension, or a definitive agreement with a different counterpart—as the clean discharge of liabilities and automatic termination of lock-ups eliminate prior contractual frictions. The document contains no forward-looking financial projections, customer concentration data, product pipeline metrics, or litigation disclosures, focusing exclusively on the structural unwind and the sponsor’s ongoing mandate to identify a replacement business combination.
What changed: Form 8-K Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, announcing Item 1.02 Termination of a Material Definitive Agreement, accompanied by Exhibit 10.1, a Termination and Release Agreement. According to the filing and Exhibit 10.1, Launch One Acquisition Corp., Launch One Sponsor LLC, Minovia Therapeutics Ltd., Natalie Yivgi-Ohana (acting in dual representative capacities), Mito US One Ltd., and Mito Sub Israel Ltd. mutually consented to terminate the Business Combination Agreement originally dated June 25, 2025 (as amended August 12, 2025, September 4, 2025, September 26, 2025, and January 6, 2026) effective January 30, 2026. The parties exercised Section 8.1(a) to void the BCA in its entirety, which simultaneously and automatically terminated all Ancillary Documents, including Voting Agreements, Lock-Up Agreements, and the Sponsor Letter Agreement. Per Section 1.3 of the released agreement, each party executed an irrevocable, global mutual release discharging all known and unknown claims, liabilities, and damages stemming from the transaction documents or proposed transactions, while expressly waiving statutory rights to pursue concealed or unanticipated causes of action. The filing notes that Section 9.1 (Waiver of Claims Against Trust) of the original BCA survives and continues to apply to the Company, Pubco, Company Merger Sub, and the Seller Representative. Launch One Acquisition Corp. and its sponsor explicitly stated they currently intend to seek alternative ways to consummate an initial business combination. No amendment to the existing redemption deadline, extension mechanism, or trust account administration is reported. Why it matters: The Termination and Release Agreement definitively halts the Minovia Therapeutics merger pathway, meaning no shareholder approval vote, tender offer, or redemption event tied to that specific combination will occur. Public shareholders retain their outstanding Class A ordinary shares ($0.0001 par value) and Warrants (exercisable at $11.50 per share) without a deal-triggered liquidity event. Because the SPAC remains in SEARCHING status with a hard deadline of January 15, 2027, the sponsor must now identify and negotiate a replacement target within the remaining contractually defined window to avoid potential liquidation and trust distribution procedures. The exhaustive mutual release and indefinite covenant not to sue permanently eliminates bilateral litigation exposure regarding the aborted transaction, while the preserved trust waiver provision maintains original shareholder protections against post-termination creditor or counterparty claims. Beyond deal mechanics, the filing confirms the intended acquisition target structure: Minovia Therapeutics Ltd. (an Israeli company limited by shares) merging into Mito US One Ltd. (Pubco) via Mito Sub Israel Ltd., with cancellation provisions outlined for outstanding In-the-Money Company Options, Company SAFEs, and other Convertible Securities. The agreement is governed by Delaware law, subjects disputes exclusively to the Chancery Court of the State of Delaware, includes a binding jury trial waiver, and was executed by Chief Executive Officer Chris Ehrlich for the SPAC, Chief Financial Officer Jurgen van de Vyver for the Sponsor, and Natalie Yivgi-Ohana for Minovia, Pubco, and the Seller Representative.
What changed: Form 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act, functioning as a prospectus-related investor communication containing a joint press release. Deal Progress & Mechanics: The filing confirms Launch One Acquisition Corp. and Minovia Therapeutics have executed a definitive business combination agreement involving Launch One, Minovia, and a newly formed Israeli entity, Mito US One Ltd. (“Pubco”). The transaction is projected for closing in the first half of 2026. Following closing, the combined entity will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol. A Registration Statement on Form F-4 has not yet been filed or declared effective by the SEC, no record date has been established for shareholder voting, and definitive proxy materials have not yet been mailed. The document does not amend the January 15, 2027 redemption deadline, alter the $10.86 per-share trust value, or modify the SPAC’s search status. Clinical & Strategic Updates: Minovia Co-founder and CEO Natalie Yivgi-Ohana, Ph.D., stated the company was granted two new U.S. patents (U.S. Patent No. 12,502,408 covering mitochondrial augmentation therapy for primary mitochondrial diseases, and U.S. Patent No. 12,329,781 covering therapy for renal diseases), with corresponding patents granted in Europe and Japan and additional applications pending globally. She asserted this strengthens the proprietary Mitochondrial Augmentation Therapy (MAT) platform and supports a long-term strategy to treat patients with high unmet medical needs. Minovia’s lead program, MNV-201 (autologous hematopoietic stem cells enriched with placental-derived mitochondria), is currently evaluated in clinical trials for Pearson Syndrome, other severe genetic mitochondrial disorders, and Myelodysplastic Syndrome. In early-stage clinical studies, Minovia claimed the therapy demonstrated a strong safety profile and signs of multi-system benefit in Pearson Syndrome patients, including improvements in growth, muscle function, hematologic stability, and quality of life. Minovia Therapeutics is chaired by John Cox. The company operates a GMP facility in Haifa, Israel, for manufacturing drug substance and product for clinical trials, and plans to expand operations to the U.S. Why it matters: For investors tracking redemption windows and deal sequencing, this Form 425 signals that the formal SEC review and shareholder solicitation phases are still preliminary, as the Form F-4 remains unfiled and unapproved. The absence of a filed proxy statement means no binding redemption terms, supplemental plan of distribution, or definitive purchase price adjustments are active, leaving the January 15, 2027 deadline structurally intact but operationally dormant for this specific transaction path. The disclosed patent grants and MNV-201 clinical data are intended to fortify the merger thesis ahead of the eventual definitive proxy mailing. Once the F-4 is declared effective, redemption calendars will become actionable, and investors will receive exact trust reconstruction mechanics, sponsor equity lock-up details, and audited pro forma financials; until then, this filing serves as a preliminary validation of asset viability rather than a binding transaction update.
What changed: Quarterly Report on Form 10-Q for Launch One Acquisition Corp. for the quarterly period ended September 30, 2025. The report updates the trust account value to $243,082,744 ($10.56 per share), reports net income of $6,220,473 for the nine months, and details the status of the Minovia Business Combination Agreement (signed June 25, 2025, amended August 12, 2025) with a termination date of December 24, 2025, and a minimum cash condition of $23 million at closing. The company has a working capital deficit of $332,033 and management expresses substantial doubt about going concern if the business combination is not completed by July 15, 2026. Why it matters: This is the first quarterly report since the Minovia deal was signed; it shows the trust is growing from interest, but the company is burning cash and faces a tight timeline to close by December 24, 2025 (under the BCA) or July 15, 2026 (under its charter). Investors need to monitor progress on the bridge financing (at least $5 million required) and the $23 million minimum cash condition. The going concern disclosure indicates risk of liquidation if the deal fails.
What changed vs 2025-08-14trust $240.6M → $243.1M +1%trust account, sponsor loans outstanding, combination deadline +21 moved · 4 with no prior record of ours
- Trust account
- $240.6M$243.1M
- Sponsor loans outstanding
- not previously extracted$308K
- Combination deadline
- 2026-07-15 · unchanged
- Going-concern doubt
- stated · unchanged
- Redeemable shares
- 23.0M · unchanged
SpacBrain reads this as $2,528,252 was added to the trust between the two filings.
The clause “9 1,056,301 Long-term prepaid insurance — 53,596 Cash and marketable securities held in Trust Account 243,082,744 235,529,521 TOTAL ASSETS $ 243,472,003 $ 236,639,418 LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND”…
The clause “Offering. Since inception through the Initial Public Offering, the Company had borrowed $ 307,974 under the IPO Promissory Note. The Company repaid $ 335,314 on July 15, 2024. The Company had no borrowings under the IPO Promissory Note”…
The clause …“of the Public Shares if the Company is unable to complete the initial Business Combination by July 15, 2026, or by such earlier liquidation date as the Company’s board of directors may approve (the “Combination Period”), subject”…
The clause …“condition, the date of mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities”…
The clause …“value; 500,000,000 shares authorized; none issued or outstanding (excluding 23,000,000 shares subject to possible redemption) as of September 30, 2025 and December 31, 2024 — — Class B Ordinary Shares, $ 0.0001 par value; 50,000,000”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Form 425 filing (deemed filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934) consisting of a press release issued by Minovia Therapeutics Ltd. and incorporated by Launch One Acquisition Corp., detailing a corporate research grant and referencing the pending Business Combination Agreement. Mechanics & Deal Progress: The filing reaffirms the existing Business Combination Agreement between Launch One Acquisition Corp. and Minovia Therapeutics, projecting a closing timeframe of 'late 2025' and stating the merged entity will trade on Nasdaq under a new ticker. It confirms that a Registration Statement on Form F-4 (incorporating the proxy statement/prospectus) will be filed to establish a record date for shareholder voting, but explicitly notes the Registration Statement has not yet been filed or declared effective by the SEC. No changes are reported to the LPAA trust value ($10.86), the redemption deadline calendar, or the January 15, 2027 liquidation date. Substance: Minovia Therapeutics announced receipt of a $350,000 grant from the Countdown for a Cure Foundation to fund research on mitochondrial blood-based biomarkers. Chief Scientific Officer Dr. Noa Sher stated the funds will advance development of the proprietary MAT platform, enabling patient identification and post-treatment monitoring, and envisioned biomarker assessments becoming available in routine checkups for individuals of all age groups. The grant finances clinical operations at Sheba Medical Center to collect blood samples from approximately 30 patients with primary mitochondrial diseases and 140 samples from healthy controls to generate a 'MitoScore.' Minovia Therapeutics attributes its main drug product, MNV-201, to current testing for Pearson Syndrome and Myelodysplastic Syndrome. According to the filing, Minovia is chaired by John Cox, led by Co-Founder and CEO Natalie Yivgi Ohana, operates a GMP manufacturing facility in Haifa, Israel, and plans expansion to the U.S. Why it matters: For LPAA investors tracking redemption mechanics and deal execution, this Rule 425 communication validates that the target is advancing R&D pipeline funding ahead of the merger and reiterates the 'late 2025' closing horizon. However, because the definitive proxy/prospectus (Form F-4) remains unfiled and uneffective, the official document that will set precise redemption windows, pro forma trust distribution mechanics, and voting thresholds has not yet been locked. Until the Registration Statement is filed and declared effective, shareholders lack finalized terms on conversion ratios or mandatory vote requirements. The grant announcement and clinical sample collection targets serve as operational validation for Minovia’s valuation narrative but do not independently alter SPAC trust accounting, sponsor conduct obligations, or the existing trust/share balance and January 15, 2027 deadline.
What changed: Quarterly report (Form 10-Q) for Launch One Acquisition Corp. for the quarterly period ended June 30, 2025. No material change to redemption mechanics or trust value. Trust per-share value increased from $10.24 (Dec 31, 2024) to $10.46 (Jun 30, 2025), reflecting earned interest of $4,996,750 in H1 2025. The search deadline remains July 15, 2026; no extension amendment was filed or proposed in this period. The Minovia Business Combination Agreement was signed on June 25, 2025 and amended on August 12, 2025 (extending bridge financing timeline from 30 to 60 days). Sponsor conduct: Sponsor agreed to subject 22.5% of its Founder Shares to transfer restrictions and potential forfeiture tied to earnout performance; no trading arrangements by directors/officers were adopted or terminated. Why it matters: The filing confirms that Launch One has a signed deal with Minovia Therapeutics Ltd. (Israeli biotech), providing a concrete path to closing by December 24, 2025 (the outside termination date). The trust is healthy at $10.46/share with $240.6M. However, the company discloses substantial doubt about its ability to continue as a going concern due to limited working capital ($263,740 cash, $183,171 surplus) and the liquidation deadline. The Minovia deal includes a $23M minimum cash condition and requires at least $5M bridge financing (deadline extended to ~60 days after signing). Shareholders should watch for the F-4 registration statement and shareholder vote.
What changed vs 2025-05-15trust $238.0M → $240.6M +1%trust account, combination deadline, going-concern doubt +11 moved · 3 with no prior record of ours
- Trust account
- $238.0M$240.6M
- Combination deadline
- not previously extracted2026-07-15
- Going-concern doubt
- stated · unchanged
- Redeemable shares
- 23.0M · unchanged
SpacBrain reads this as $2,559,713 was added to the trust between the two filings.
The clause “056,301 Long-term prepaid insurance 2,006 53,596 Cash and marketable securities held in Trust Account 240,554,492 235,529,521 TOTAL ASSETS $ 241,152,118 $ 236,639,418 LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND”…
The clause …“of the Public Shares if the Company is unable to complete the initial Business Combination by July 15, 2026, or by such earlier liquidation date as the Company’s board of directors may approve (the “Combination Period”), subject”…
The clause …“to cease operations and liquidate the Trust Account. These conditions raise substantial doubt about the Company’s ability to continue as a going concern one year from the date that the accompanying unaudited condensed financial”…
The clause …“value; 500,000,000 shares authorized; none issued or outstanding (excluding 23,000,000 shares subject to possible redemption) as of June 30, 2025 and December 31, 2024 — — Class B Ordinary Shares, $ 0.0001 par value; 50,000,000 shares”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: SEC Schedule 13G/A — a routine compliance exhibit amending a beneficial ownership report for equity interests exceeding the five-percent statutory threshold. MMCAP International Inc. SPC and MM Asset Management Inc. filed an amendment to update their LPAA position. The provided excerpt lists only the filing type and holder names; it does not disclose the percentage of shares held, transaction dates, acquisition volume, or the stated purpose of the amendment. Consequently, the document does not alter LPAA’s redemption procedures, modify the $10.86-per-share trust balance, shift the January 15, 2027 termination deadline, accelerate or pause a business combination search, or introduce new sponsor conduct. These mechanical observations derive entirely from the header text supplied. Why it matters: Block owners above the five-percent benchmark frequently track sponsor activity and may align with merger targets, but without the numerical body of the 13G/A, the amendment cannot be weighted against redemption waves, extension voting windows, or capital call timelines. Investors monitoring trust preservation, deadline risk, or deal execution should treat this as a structural disclosure update rather than an operational catalyst. Any substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel are absent from the filing excerpt. Full impact would require the complete exhibit detailing share counts, cost basis, and investment intent.
What changed: Schedule 13G beneficial ownership report. The filing identifies Barclays PLC as the reporting holder but contains no statements, amendments, or data pertaining to redemption deadlines, trust value, extension provisions, business combination deal progress, or sponsor conduct. Why it matters: The document contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel; it serves exclusively as a regulatory ownership disclosure establishing Barclays PLC's stake without impacting Launch One Acquisition Corp.’s operational timeline, trust account mechanics, or target search parameters.
What changed: SEC Form 425 prospectus communication and investor press release filed by Launch One Acquisition Corp. under Rule 425 to disseminate preliminary clinical data from its merger target, Minovia Therapeutics Ltd. Launch One confirmed entry into a definitive business combination agreement with Minovia, projecting closing for late 2025. The filing makes no alterations to redemption mechanics, trust balance calculations, extension voting rules, or sponsor conduct standards. No amendments to the SEARCHING status deadline (2027-01-15) are reported. The formal Form F-4 Registration Statement and proxy statement, which will govern shareholder redemption rights, record dates, and voting, remain unfiled and uneffective. Why it matters: The communication functions as permissible solicitation material ahead of the F-4, providing clinical milestones intended to shape shareholder voting and redemption calculus. Co-founder and CEO Natalie Yivgi-Ohana stated the Phase 2 trial met its primary safety endpoint, reporting zero treatment-related severe adverse events and no anti-mitochondrial antibodies. Chief Scientific Officer Noa Sher reported all adverse events were transient, with most resolving within four days, and attributed the majority to the pre-administration apheresis procedure required to procure cells. The Company states that at a six-month follow-up, two of the first three patients experienced improved height standard deviation scores relative to pre-treatment baselines, with quality of life scores likewise improving for those two patients; this efficacy signal relies on a novel endpoint identified through a Children’s Hospital of Philadelphia natural history study supported by Minovia funding. Enrollment continues with trial completion expected before the end of 2025. Additional data from two compassionate-use Kearns-Sayre syndrome patients also showed favorable safety and improved quality of life. The FDA granted Fast Track and Rare Pediatric Disease Designations; the Company expects to initiate registrational studies in 2026 and notes historic pediatric priority review vouchers commanded prices exceeding US$100 million, though voucher programs are currently paused awaiting Congressional reauthorization. The filing’s forward-looking risk section explicitly warns of potential Business Combination Agreement termination, financing shortfalls, regulatory delays, stock exchange listing failures, and the risk that estimated shareholder redemptions, purchase price adjustments, or cash-position constraints could materially disrupt projected economic outcomes.
What changed: A Form 8-K filed on July 1, 2025, reporting the entry into a material definitive agreement (Item 1.01) - specifically, a Business Combination Agreement (BCA) dated June 25, 2025, between SPAC Launch One Acquisition Corp. (LPAA) and Minovia Therapeutics Ltd., a clinical-stage biotechnology company developing mitochondrial therapies. The SPAC announced a definitive business combination with Minovia Therapeutics. The combined entity will be named Mito US One Ltd. (Pubco) and list on Nasdaq. Key terms include: (a) base merger consideration of $180 million to Minovia's security-holders, payable in Pubco ordinary shares valued at the Redemption Price; (b) an earnout of up to $57.5 million in Pubco shares if Pubco's VWAP exceeds $11.50 for five consecutive days or if a Phase 3 trial for Pearson syndrome begins within five years post-close; (c) a required minimum cash condition of at least $23 million at closing (including trust cash post-redemptions plus Transaction Financing proceeds); (d) a requirement to secure at least $5 million in Bridge Financing within 30 days of signing; (e) the Sponsor agreed to subject 22.5% of its founder shares (1,293,750 shares) to the same earnout milestones and potential forfeiture; (f) an outside termination date of December 24, 2025; (g) no termination fee; (h) a trust account waiver from Minovia and Pubco; and (i) a lock-up of one year for Minovia insiders and 3%+ holders on their Pubco shares, with early release if Pubco shares trade above $12.00 for 20 of 30 days starting 150 days post-close. Why it matters: This filing moves LPAA from 'SEARCHING' to a definitive deal with a specific target, valuation, and timeline. It establishes a minimum cash condition of $23 million, meaning the deal can fail if too many public shareholders redeem or if Transaction Financing falls short. The requirement for at least $5 million in Bridge Financing within 30 days is a near-term risk of termination. The sponsor's earnout shares are aligned with the target's milestones, but the absence of a termination fee and the existence of a patent-based termination right (FTO Opinion) are unusual and provide avenues for either party to walk away. The 1-year lock-up for company insiders is standard. The trust per-share value of $10.86 provides a significant premium to the $11.50 earnout threshold.
outside datenothing moved · 1 with no prior record of ours
- Outside date
- not previously extracted2025-12-24
SpacBrain reads this as the agreement may be terminated from 2025-12-24.
The clause …“to the Closing set forth in Article VII have not been satisfied or waived by December 24, 2025 (the “ Outside Date ”); provided, however, that the right to terminate this Agreement under this Section 8.1(b) shall not be available to a”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Form 8-K Current Report filed by Launch One Acquisition Corp. (SPAC) to disclose its entry into a definitive Business Combination Agreement (BCA) with Minovia Therapeutics Ltd., an Israeli biotech company focused on mitochondrial therapies. The filing includes the full BCA, forms of Lock-Up and Voting Agreements, and a Sponsor Letter Agreement. LPAA was in SEARCHING status; this filing announces a definitive merger. The deal values Minovia at $180 million in base equity consideration (payable in Pubco shares valued at the Redemption Price), plus up to $57.5 million in contingent Earnout Shares. The SPAC's trust held at least ~$239.7 million as of signing. A minimum cash condition of $23 million at closing is required (trust cash after redemptions plus new financing, minus expenses). A $5 million bridge financing must close within 30 days of signing (by ~July 25, 2025) or either side can terminate. The outside date to close is December 24, 2025. Sponsor will subject 22.5% of its founder shares to earnout-like restrictions and potential forfeiture. Why it matters: This is the fundamental event for a SPAC in SEARCHING status: it now has a target. The trust value is high ($10.86/share), creating a large potential redemption overhang. The $23 million minimum cash condition is a critical threshold for viability post-close and depends heavily on redemptions and the ability to raise $23M+ in new PIPE/backstop financing. The earnout structure (shares tied to $11.50 stock price or Phase 3 trial start) provides a long-duration incentive. The 2025-12-24 outside date creates a hard deadline. The lack of post-closing indemnification for the target's reps is a notable risk factor for public shareholders.
outside datenothing moved · 1 with no prior record of ours
- Outside date
- 2025-12-24 · unchanged
The clause …“to the Closing set forth in Article VII have not been satisfied or waived by December 24, 2025 (the “ Outside Date ”); provided, however, that the right to terminate this Agreement under this Section 8.1(b) shall not be available to a”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Form 425 Rule 425 communication consisting of a joint press release filed by Launch One Acquisition Corp. and issued by Minovia Therapeutics Ltd. on June 30, 2025, announcing FDA designations for MNV-201 and updating stakeholders on an executed definitive business combination agreement. The filing confirms that Launch One and Minovia recently entered into a definitive business combination agreement, with both companies projecting a transaction closing for late 2025. According to the document, the combined entity will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol. While the text does not alter LPAA’s existing redemption calendar, trust balance, or sponsor compensation terms, it establishes the next procedural milestone: both parties intend to file a Registration Statement on Form F-4 with the SEC to incorporate a preliminary proxy statement/prospectus. Following SEC effectiveness, definitive proxy materials will be distributed to stockholders for a vote. No extensions, trust adjustments, or sponsor conduct shifts are reported. Why it matters: The publication materially advances the deal’s execution timeline relative to LPAA’s January 15, 2027 search deadline, while positioning a pending Form F-4 filing that will deliver exact redemption mechanics, pro forma trust valuation, and proxy materials. According to Minovia Co-founder and CEO Natalie Yivgi-Ohana, Ph.D., the FDA’s grant of Fast Track and Rare Pediatric Disease Designations for the Phase 2 MNV-201 trial in Pearson Syndrome validates the clinical approach and could decrease time-to-market. The document further notes that a pediatric priority review voucher associated with the designation has historically commanded prices in excess of US$100 million, though the program remains on hold awaiting congressional reauthorization. Minovia states plans to finalize pivotal trial designs and initiate registrational studies in 2026, operates a GMP manufacturing facility in Haifa, Israel, is expanding to the U.S., tests MNV-201 for Myelodysplastic Syndrome alongside Pearson Syndrome, and maintains John Cox as chair of its board. For investors tracking redemption behavior, the forthcoming proxy distribution represents the critical inflection point where trust value, redemption windows, and sponsor conduct terms become contractually binding, making this communication a structural prerequisite to actionable voting decisions rather than a standalone term revision.
What changed: Form 8-K filed pursuant to Rule 425 furnishing a joint press release (Exhibit 99.1) and a confidential investor presentation (Exhibit 99.2) that announce the execution of a definitive Business Combination Agreement between Launch One Acquisition Corp. and Minovia Therapeutics Ltd. This filing formally initiates the SPAC merger mechanics and conditional timeline: it establishes a two-step merger structure creating a combined entity named Mito US One Ltd., sets a pre-money equity valuation for Minovia at $180 million (which the filing notes will be increased by a minimum $5 million bridge financing payable within 30 days and up to $57.5 million in aggregate contingent earnout shares valued at the public 'Redemption Price'), anticipates at least $18 million in PIPE investments at closing, and confirms the trust account currently holds approximately $239.7 million in cash whose ultimate availability to the combined company is explicitly conditioned on the volume of public shareholder redemptions. The signing officially triggers the obligation to file a Form F-4 registration statement containing a proxy statement/prospectus, which will lock in the record date, voting procedures, and final redemption deadline relative to the sponsor’s stated January 15, 2027 termination window. Why it matters: According to the press release authored by Launch One CEO Chris Ehrlich and Minovia Co-Founder and CEO Natalie Yivgi-Ohana, the transaction positions the combined company to advance lead product MNV-201 through a Phase 2 trial for Pearson Syndrome and a Phase 1b study for low-risk Myelodysplastic Syndrome, citing awarded FDA Fast Track and Rare Pediatric Disease designations. The presentation, prepared jointly by the parties, attributes preclinical efficacy claims—including reversed aging phenotypes in aged mouse kidneys, improved locomotor function, and stabilized renal and hematologic markers in humans—to internal studies and third-party literature, noting that Minovia’s management reports 23 patients have been treated to date with no documented drug-product related adverse events. Leadership claims a regulatory-aligned pathway to launch MAT-based longevity offerings through global clinic partnerships in 2026 using a recurring revenue-share model, while disclosing a cumulative historical capital raise of approximately $50 million (broken down as roughly $33 million in private equity and $20 million in non-dilutive R&D collaboration with Astellas Pharma). The filing does not modify the existing trust balance or extension rules but supplies the critical valuation parameters, redemption pricing formula, and expected capital deployment schedule ($25 million targeted over 24 months) that determine whether public shareholders receive their pro rata trust portion or participate in the combined company’s equity upside.
pipenothing moved · 1 with no prior record of ours
- PIPE
- not previously extracted$18.0M
The clause …“Combination. In addition, the parties are currently anticipating at least $18 million in PIPE investments at closing of the Business Combination, in addition to remaining cash held in Launch One’s trust account after shareholder”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Form 8-K (Item 7.01 Regulation FD Disclosure) announcing the execution of a definitive Business Combination Agreement with Minovia Therapeutics Ltd., furnished alongside a joint press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2). Launch One advanced from a search mandate to a named target. The filing establishes a $180 million pre-money valuation for Minovia, mandates a bridge financing of at least $5 million within 30 days, anticipates PIPE investments of at least $18 million at closing, and outlines a potential earnout of up to $57.5 million for Company equity holders. The accompanying press release states the SPAC’s trust account holds approximately $239.7 million in cash. Chris Ehrlich executed the filing as Chief Executive Officer. XBRL metadata confirms warrants carry an exercise price of $11.50 per share. Why it matters: This 8-K initiates the proxy solicitation and Form F-4 registration process, dictating the mechanics for shareholder redemptions and votes against the January 15, 2027 deadline. The transaction structure conditions available trust proceeds of approximately $239.7 million, alongside a mandatory bridge financing of at least $5 million and anticipated PIPE of at least $18 million, on satisfying customary closing conditions to fund pipeline milestones. In the press release and presentation, sponsors characterize the addressable opportunity as a '$1 trillion+' longevity and regenerative medicine market, noting their advisory group has successfully completed eight prior SPAC mergers. Minovia Co-Founder and CEO Natalie Yivgi-Ohana asserts the MAT platform delivers multi-system benefits and durable safety across 23 treated patients, while stating total capital raised to date stands at '~$50 million,' inclusive of '~$33 million in equity' and '$20 million in non-dilutive strategic R&D collaboration with Astellas Pharma.' Launch One CEO Chris Ehrlich adds that U.S.-based GMP manufacturing is scheduled for end-of-2025 readiness.
What changed: Quarterly report (Form 10-Q) for the period ended March 31, 2025, filed by Launch One Acquisition Corp. (LPAA), a blank check company still searching for a business combination. Trust Account increased to $237,994,779 ($10.34 per share, redemption value approximately $10.35) from $235,529,521 ($10.24 per share) due to interest income of $2,449,036 and unrealized gain of $16,222. Net income of $2,287,413 for the quarter. Operating cash used $181,415; working capital surplus decreased to $795,071 from $850,338. No business combination target selected. Going concern uncertainty reiterated. Deadline remains July 17, 2026. No changes to sponsor agreements, redemption terms, or warrant structure. Why it matters: Trust per-share value continues to grow, providing a slightly higher redemption floor for shareholders. However, cash burn and limited working capital may pressure the company to complete a deal or raise additional funds. The ongoing going concern warning highlights the urgency of finding a target within the 24-month window. No extension or deal announced, so the clock continues to run.
What changed vs 2024-11-13trust $232.8M → $238.0M +2%trust account, going-concern doubt, redeemable shares1 moved · 2 with no prior record of ours
- Trust account
- $232.8M$238.0M
- Going-concern doubt
- stated · unchanged
- Redeemable shares
- 23.0M · unchanged
SpacBrain reads this as $5,199,547 was added to the trust between the two filings.
The clause “56,301 Long-term prepaid insurance 27,801 53,596 Cash and marketable securities held in Trust Account 237,994,779 235,529,521 TOTAL ASSETS $ 238,948,966 $ 236,639,418 LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND”…
The clause …“of the Company. Management has determined that the liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities”…
The clause …“value; 500,000,000 shares authorized; none issued or outstanding (excluding 23,000,000 shares subject to possible redemption) as of March 31, 2025 and December 31, 2024 — — Class B ordinary shares, $ 0.0001 par value; 50,000,000”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Schedule 13G/A amendment documenting beneficial ownership filings attributed to MMCAP International Inc. SPC and MM Asset Management Inc. The excerpt records an update to a prior Section 13(d) disclosure identifying the reporting entities. It contains no numerical disclosures, share counts, percentage-of-class calculations, acquisition dates, purchase prices, or transaction history typically required to assess holder behavior or potential activist positioning. Why it matters: Against LPAA’s stated search framework ($10.86 trust per share, January 15, 2027 deadline, and active business combination pursuit), this filing delivers no signal regarding redemption thresholds, trust account yields or disbursements, extension ballot timing, target due diligence, or sponsor governance. It makes no claims about customer concentrations, revenue multiples, market sizing, strategic pivots, technology roadmaps, partnership frameworks, litigation exposure, or executive personnel changes. Routine Schedule 13G/A amendments frequently refresh regulatory ownership records when internal fund restructuring or custodial routing changes occur, yet they do not mechanically alter SPAC liquidation clocks, trigger mandatory tender offers, or advance merger execution. Without disclosed threshold crossings or explicit intent statements, the exhibit functions as a compliance maintenance record rather than a catalyst for investor action.
What changed: Annual Report (Form 10-K) for the fiscal year ended December 31, 2024. First annual report since IPO. Reports no business combination target identified. Trust account balance $235,529,521 ($10.24 per share). Net income $5,129,519 from interest. Cash outside trust $850,338. Deadline to complete initial business combination is July 15, 2026 per charter, with Nasdaq delisting risk if not completed by July 11, 2027. No material changes in operations. Why it matters: Provides baseline financials and trust value for redemption calculations. Confirms the SPAC is still searching with 24-month window from IPO. Trust per share is $10.24, slightly above $10.00. The company may seek an extension, which would require shareholder vote and redemption rights. The filing also details insider trading policies, clawback policy, and independence of directors.
What changed: Routine compliance exhibit: a Schedule 13G/A amended beneficial ownership report. The excerpt identifies three affiliated reporting persons—AQR Capital Management, LLC; AQR Capital Management Holdings, LLC; and AQR Arbitrage, LLC—but provides no share quantities, aggregate percentages, transaction dates, or stated amendment purposes because the text terminates before standard disclosure items. Why it matters: Against the backdrop of the stated deadline and trust value, this filing discloses nothing regarding redemption mechanics, trust account movements, extension filings, deal execution timelines, or sponsor conduct. The listed entities point to a coordinated arbitrage reporting structure; without explicit merger or tendering language, the amendment most plausibly reflects routine accounting updates, internal book restructuring, or a negligible proportional variation necessitating an amended submission. Investors should watch subsequent filings for threshold crossings that include acquisition intent or synchronized block transactions indicative of PIPE underwriting or merger closing activities.(flagged for human review)
What changed: Routine compliance exhibit: Schedule 13G/A amendment filing a beneficial ownership report. Picton Mahoney Asset Management submitted an amended schedule disclosing beneficial ownership of LPAA common stock. The excerpt provides no share counts, percentage thresholds, purchase or sale mechanics, redemption elections, extension voting, or trust distribution details. Why it matters: Institutional amendments to Section 13(G) track capital commitment signals for a SPAC still searching. Picton Mahoney Asset Management’s filing indicates ongoing position monitoring but supplies no metrics to evaluate impact on the stated $10.86 trust value per share, the January 15, 2027 deadline, or sponsor negotiation leverage. The document contains no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel.
What changed: Schedule 13G/A, an amendment to a beneficial ownership report filed with the SEC by MMCAP International Inc. SPC and MM Asset Management Inc. The excerpt provides only the filing designation, SEC index number, and holder identifiers. It contains no amended share counts, percentage ownership figures, acquisition or disposition dates, or stated investment purpose that typically drive a 13G/A update. Under Securities Exchange Act regulations, the amendment format exists to report material shifts in reporting obligation status or economic interest, but the submitted text itself discloses neither quantities nor transactions. Why it matters: This document tracks standard institutional equity reporting compliance and does not address LPAA’s redemption deadline of 2027-01-15, its trust value per share of $10.86, its SEARCHING status, or any sponsor-led extension, business combination negotiation, or redemption window mechanics. Neither the sponsor group, LPAA executives, nor the listed holding companies assert claims regarding customers, revenue, market size, technology, partnerships, litigation, or personnel in this excerpt. Without the attached amendment narrative, there is no verifiable indication of coordinated activism, voting blocs, or conditions that would alter cash-out eligibility or target selection timelines. The filing remains a routine post-holdings disclosure update with no direct operational or financial bearing on the trust account or merger calendar.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.